<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HPV bivalent vaccine &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/hpv-bivalent-vaccine/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 14 Jan 2026 16:03:40 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>HPV bivalent vaccine &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>HPV-16/18 Vaccine Alters High-Risk HPV Evolution</title>
		<link>https://bioengineer.org/hpv-16-18-vaccine-alters-high-risk-hpv-evolution/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 16:03:36 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[high-risk HPV natural history]]></category>
		<category><![CDATA[HPV bivalent vaccine]]></category>
		<category><![CDATA[HPV type replacement` **Bu etiketlerin seçilme nedeni:** 1. **adult HPV vaccination:** Çalışmanın 18-45 yaş arası yetişkin kadınlarda yapıldığı]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket (virgülle ayrılmış): `adult HPV vaccination]]></category>
		<category><![CDATA[viral persistence clearance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/hpv-16-18-vaccine-alters-high-risk-hpv-evolution/</guid>

					<description><![CDATA[In a groundbreaking new study published in Nature Communications, researchers have explored the dynamic landscape of high-risk human papillomavirus (HPV) infections following administration of the HPV-16/18 bivalent vaccine in women aged 18 to 45. This comprehensive investigation sheds unprecedented light on the natural history of various oncogenic HPV types in a demographic that represents a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316864</post-id>	</item>
	</channel>
</rss>
